PlainPharmaWatch

CMS Open Payments · Program Year 2024

Revance Therapeutics, Inc.

Revance Therapeutics, Inc. reported $1,164,721.91 across General Payments, Research, and Ownership to 21,446 physicians and teaching hospitals across 21,446 transactions.

See the rankings → How this is sourced
$1.2M
All-tracks total
21,446
Transactions
21,446
Recipients
#587
of 1,925 companies

Revance Therapeutics, Inc. reported $1,164,721.91 across all CMS Open Payments tracks (General + Research + Ownership) to 21,446 physicians and teaching hospitals in Program Year 2024 - ranking #587 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,164,721.91, averaging $54.31 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer revance-therapeutics-inc Revance Therapeutics, Inc.

$1.2M · #587/1,925 · 0.0% industry · PY2024

  • TOT $1.2M
  • RANK #587
  • SHARE 0.0%
  • TXN 21,446
  • RCP 21,446
  • CAT 3
  • GEN $1.2M
  • TOP1 2.3%
  • PY 2024

Volume peers

Nearest volume peer: New Wave Endo-Surgical Corp. ($1.2M)

Organ Recovery Systems, Inc.$1.2MNew Wave Endo-Surgical Corp.$1.2MRevance Therapeutics, Inc. (…$1.2MOcclutech US LLC$1.2MNoah Medical Corporation$1.2M
All-tracks payment totals near Revance Therapeutics, Inc. (CMS Open Payments PY2024)

Revance Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Revance Therapeutics, Inc.

Averaging $54.31 per transaction and $54.31 per recipient, Revance Therapeutics, Inc.'s Program Year 2024 total comes to $1,164,721.91 across 21,446 transactions and 21,446 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #587 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Food and Beverage" leads the 3-category general-payment breakdown below at $1.2M (99.9% of General Payments, 21,429 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Food and Beverage" leads Revance Therapeutics, Inc.'s 3-category general-payment breakdown at $1.2M, 99.9% of the reported total.

How Revance Therapeutics, Inc. divides its payments

How the reported total splits across payment categories

1. Food and Beverage$1.2M2. Education$852.933. Gift$323.30
Payment Type Amount Transactions
Food and Beverage $1.2M 21,429
Education $852.93 14
Gift $323.30 3

Recipient Concentration in General Payments

The five largest recipient relationships account for $90,405.20 (7.8%) of $1,164,721.91 in this company's General Payments records across 7,236 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Revance Therapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Annie Gonzalez$26.5KAnnie Chiu$25.7KGloria Jackie Yee$13.2KAva Shamban$12.7KRitu Batra$12.3K
  1. 1

    Annie Gonzalez

    $26,536.09 across 20 reported transactions

  2. 2

    Annie Chiu

    $25,743.57 across 8 reported transactions

  3. 3

    Gloria Jackie Yee

    $13,151.34 across 24 reported transactions

  4. 4

    Ava Shamban

    $12,692.33 across 12 reported transactions

  5. 5

    Ritu Batra

    $12,281.87 across 5 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Revance Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Revance Therapeutics, Inc..

Alvogen Inc

HHI 24

OptumHealth Care Solutions, LLC

HHI 24

A-dec, Inc.

HHI 24

Medical Device Business Services, Inc.

HHI 24

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Revance Therapeutics, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Revance Therapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.